Anavex life sciences announces oral blarcamesine cognitive resilience results approximating normal aging in new precision medicine clinical data from phase iib/iii alzheimer's disease trial

New clinical precision medicine population 48-week data demonstrates unprecedented cognitive stabilization in early alzheimer's disease

AVXL Ratings Summary

AVXL Quant Ranking